Oventus Medical Ltd. announced it has signed its first material contracts with Canadian sleep medicine groups who will adopt the company's O2Vent® Sleep Treatment Platform. The launch with the two groups, which represent 7 clinical delivery sites, is scheduled for July 2019. The exclusive supply agreements require that each of the 7 sites must deliver minimum monthly quotas of 20 devices from the O2Vent® Sleep Treatment Platform, which will be delivered to patients using the `lab in lab' model. The Oventus Sleep Treatment Platform encompasses the O2Vent® oral therapeutic device, and the unique valve accessories, ExVent™ and O2Vent® OnePAP™.